About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR

Company Statement

Biocon retains economic interest in Etanercept collaboration with Mylan

Bengaluru, India, June 28, 2018

“This is in reference to the announcement by our global partner, Mylan, of a commercialization agreement with Lupin for biosimilar Etanercept for certain markets. Biocon clarifies that it retains its economic interest in this arrangement vis-à-vis Mylan in accordance with its existing collaboration agreement and would benefit from the opportunity to accelerate commercialization of this product.”  -Company Spokesperson


<< Back




Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
  Report adverse event/side effects and product complaints    
  * Disclaimer            © 2018, Biocon. All Rights Reserved